Published 1 year ago

Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

Summary by Ground News

Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157/V940, in combination with Keytruda, for the adjuvant treatment of patients with high-risk melanoma after complete resection. FDA's decision was backed by data from a phase 2b trial, dubbed KEYNOTE-942/mRNA- 4157-P201.

0 Articles

All

Left

Center

Right

Irish Independent

Moderna’s skin cancer therapy receives breakthrough tag after promising study results

Moderna Inc has said its experimental personalised mRNA skin cancer vaccine in combination with Merck drug Keytruda has received breakthrough therapy designation from US regulators as an additional treatment for high risk patients.

1 year ago·Ireland

Read Full Article

CNBC

Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine

CNBC's Meg Tirrell reports on news from Moderna and Merck.

1 year ago·United States

Read Full Article

ARY News

Moderna's skin cancer therapy receives breakthrough tag

Moderna's mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine

1 year ago·Pakistan

Read Full Article

Seeking Alpha

Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

The U.S. Food and Drug Administration ((FDA)) granted breakthrough therapy designation to Moderna (MRNA) and Merck's (MRK) personalized mRNA cancer vaccine mRNA-4157/V940, in...

1 year ago·United States

Read Full Article

Medical Dialogues

Moderna-Merck gets USFDA Breakthrough Therapy Designation for personalized mRNA cancer vaccine in combination with KEYTRUDA to treat high-risk melanoma

Cambridge: Moderna, Inc. and Merck have announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted...

1 year ago·New Delhi, India

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right2Center1Last Updated1 year agoBias Distribution

67% Right

Bias Distribution

67% of the sources lean Right

67% Right

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

0 Articles

0 Articles

Moderna’s skin cancer therapy receives breakthrough tag after promising study results

Moderna’s skin cancer therapy receives breakthrough tag after promising study results

Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine

Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine

Moderna's skin cancer therapy receives breakthrough tag

Moderna's skin cancer therapy receives breakthrough tag

Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

Moderna-Merck gets USFDA Breakthrough Therapy Designation for personalized mRNA cancer vaccine in combination with KEYTRUDA to treat high-risk melanoma

Moderna-Merck gets USFDA Breakthrough Therapy Designation for personalized mRNA cancer vaccine in combination with KEYTRUDA to treat high-risk melanoma

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics